SCHEMBL2067349

SCHEMBL2067349

COc1ccc(COc2ccc(-c3ccc(N(C)C)cc3)cc2/C=C2\SC(=S)NC2=O)cc1

nearest known ligand 0.81

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTP4A3 O75365 9/20 0.81
▸ ADAMTS5 Q9UNA0 2/20 0.64
▸ CISD1 Q9NZ45 2/20 0.54
▸ PTPN1 P18031 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ CRHBP P24387 1/20 0.49
▸ CRHR2 Q13324 1/20 0.49
▸ CSNK2A2 P19784 1/20 0.49
▸ CLK1 P49759 1/20 0.49
▸ CSNK2B P67870 1/20 0.49
▸ CSNK2A1 P68400 1/20 0.49
▸ DYRK1A Q13627 1/20 0.49
▸ DYRK1B Q9Y463 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067350 1.00 PTP4A3 (0.81) PTP4A3ADAMTS5CISD1PTPN1CA2
SCHEMBL10090269 0.90 PTP4A3 (1.00) PTP4A3ADAMTS5CISD1PTPN1MEN1
SCHEMBL2065003 0.90 PTP4A3 (1.00) PTP4A3ADAMTS5CISD1PTPN1MEN1
SCHEMBL2065002 0.90 PTP4A3 (1.00) PTP4A3ADAMTS5CISD1PTPN1MEN1
SCHEMBL10090266 0.89 PTP4A3 (0.85) PTP4A3ADAMTS5CISD1PTPN1CA2
SCHEMBL2067676 0.81 PTP4A3 (0.77) PTP4A3ADAMTS5CISD1PTPN1MEN1
SCHEMBL2067675 0.81 PTP4A3 (0.77) PTP4A3ADAMTS5CISD1PTPN1MEN1
SCHEMBL10090227 0.81 PTP4A3 (0.75) PTP4A3ADAMTS5CISD1PTPN1CA2
SCHEMBL2064654 0.81 PTP4A3 (0.75) PTP4A3ADAMTS5CISD1PTPN1CA2
SCHEMBL2064655 0.81 PTP4A3 (0.75) PTP4A3ADAMTS5CISD1PTPN1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US claimed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US claimed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885ADAMTS5 4123/4885CISD1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback